OR WAIT null SECS
The Lensar Laser System for refractive cataract surgery (Lensar Inc.) has received 510(k) clearance from the FDA for the execution of arcuate incisions during cataract surgery.
Orlando, FL-The Lensar Laser System for refractive cataract surgery (Lensar Inc.) has received 510(k) clearance from the FDA for the execution of arcuate incisions during cataract surgery.
The laser system is now cleared to perform both corneal and arcuate incisions, as well as lens fragmentation and anterior capsulotomy (with or without phacofragmentation), during cataract surgery. The system enables cataract surgeons to execute arcuate incisions with precision and repeatability through the company’s featured proprietary Augmented Reality technology.
“The execution of the arcuate incision with the proprietary Augmented Reality Imaging system and advanced laser technology is one of the key recent advances in the area of cataract surgery. Until recently, these small and challenging incisions in the cornea were made manually, leading to variability in predictable outcomes,” said Louis “Skip” Nichamin, MD, a member of Lensar’s medical advisory board. “Lensar’s advanced technology platform will help cataract surgeons achieve consistent, predictable arcuate incision outcomes, regardless of the challenges and complexity of the procedure.”
The platform showcases Lensar’s next-generation differentiating augmented reality technology, consisting of proprietary high-resolution imaging and measurement technology to provide precise biometric information and 3D reconstruction of the anterior anatomy of the eye. The laser system provides precise capsulotomy incision size, shape, and location, thereby enhancing effective IOL lens positioning and fitting for each individual patient, leading to optimized patient outcomes, according to the company.
For more articles in this issue of Ophthalmology Times eReport, click here.